Search

Karel L Petrak

from Houston, TX
Age ~82
Get Report
Also known as:
Karel L Patrak, Kellie Petrak, Petrak Petrak, Karel Petral
Phone and address:
707 Knox St, Houston, TX 77007
(713) 863-1280
Connected to:
Gary L Petrak, 71Gregory H Petrak, 68Jill N Petrak, 77Jozef M Petrak, 80Linda M Petrak, 61Margaret L Petrak, 87Michael Petrak, 40Suzanne Petrak, 66Valorie Petrak, 69Rita M Petrakes, 95

Karel Petrak Phones & Addresses

  • 707 Knox St, Houston, TX 77007 (713) 863-1280 (713) 861-2418 (713) 868-1523
  • 2121 Mid Ln APT 538, Houston, TX 77027 (832) 785-2488
  • 30819 Melita Dr, Spring, TX 77386 (281) 298-6072 (281) 364-7326
  • Stanley, ID
  • Oshkosh, WI
  • Hamilton, OH
  • Brookeland, TX
  • Brentwood, NY

Resumes

Resumes

Karel Petrak Photo 1

Karel Petrak

View page
Position:
VP R&D at Agennix, Inc., Owner at PJP Innovations, Inc.
Location:
Houston, Texas Area
Industry:
Pharmaceuticals
Work:
Agennix, Inc.
VP R&D
PJP Innovations, Inc.
Owner
Valentis, Inc. (formerly GeneMedicine, Inc.) 1994 - 2000
Project Director
Education:
University of Sussex 1969 - 1972
Skills:
Specific interests: drug delivery
site-specific/site-selective drug delivery
gene delivery and gene therapy
innate immune response
Interests:
business opportunities consulting
Honor & Awards:
SOME $ 10 MM IN HIH GRANT FGUNDING
Karel Petrak Photo 2

Chief Scientific Officer

View page
Location:
Houston, TX
Industry:
Biotechnology
Work:
Nangiotx
Chief Scientific Officer
Harris County Hospital District Sep 2011 - May 2013
Vice President, Strategic Grants Development
Agennix Jan 2000 - May 2010
Vice President For Research and Development
Pjp Innovations Sep 1997 - Sep 2007
President
Genemedicine 1995 - 1999
Project Leader and Director
Education:
University of Sussex 1969 - 1974
Czech Technical University In Prague
Master of Science, Masters, Organic Chemistry University of Sussex
Skills:
Biotechnology
Drug Development
Clinical Development
Biopharmaceuticals
Pharmaceutical Industry
R&D
Technology Transfer
Clinical Research
Fda
Drug Discovery
Assay Development
Drug Delivery
Glp
Regulatory Affairs
Pharmaceutics
Infectious Diseases
Commercialization
Start Ups
Lifesciences
Strategy
Vaccines
Gmp
Molecular Biology
Strategic Planning
Clinical Trials
Immunology
Oncology
Knowledge Management
Leadership
Healthcare
Healthcare Management
Quality Management
Translational Research
Research
Cancer
Cro
Genomics
Validation
21 Cfr Part 11
Drug Targeting
Developing Drugs Suitable For Site Specific Delivery
Pre Clinical and Clinical Study Design
Project Development and Management
Problem Solving
Grant Administration From Project Design To Successful Grant Application
Innovation
Lactoferrins and Recombinant Human Lactoferrin
Structure Versus Property Relationship
Creative Writing For Success
Interests:
Science and Technology
Education
Environment
Health
Languages:
English
Spanish
Russian
Certifications:
Duolingo Spanish Fluency: Advanced (Estimated)
Duolingo Spanish Fluency: Intermediate (Estimated)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Karel Petrak
CTO
Agennix Incorporated
Commercial Physical Research · Nonclassifiable Establishments · Security Brokers and Dealers · Research & Development in Biotechnology
8 Greenway Plz, Houston, TX 77046
(713) 552-1091, (713) 552-0795

Publications

Us Patents

Composition Of Lactoferrin Related Peptides And Uses Thereof

View page
US Patent:
7183381, Feb 27, 2007
Filed:
Oct 26, 2005
Appl. No.:
11/258767
Inventors:
Atul Varadhachary - Houston TX, US
Peter Glynn - Houston TX, US
Karel Petrak - Houston TX, US
Jose Engelmayer - Houston TX, US
Assignee:
Agennix, Inc. - Houston TX
International Classification:
C07K 1/00
US Classification:
530350
Abstract:
The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.

Lactoferrin In The Reduction Of Pain

View page
US Patent:
7323443, Jan 29, 2008
Filed:
Dec 11, 2003
Appl. No.:
10/733621
Inventors:
Atul Varadhachary - Houston TX, US
Karel Petrak - Houston TX, US
Assignee:
Agennix Inc. - Houston TX
International Classification:
A61K 38/00
A61K 38/40
US Classification:
514 6, 514 8, 530350, 530395, 530400, 424 91, 424 851
Abstract:
The present invention relates to methods of using lactoferrin (LF) to reduce pain in conditions associated with severe or intractable pain by administering a composition of lactoferrin either alone or in combination with other therapy for pain.

Composition Of Lactoferrin Related Peptides And Uses Thereof

View page
US Patent:
7420033, Sep 2, 2008
Filed:
Feb 22, 2007
Appl. No.:
11/677796
Inventors:
Atul Varadhachary - Houston TX, US
Peter Glynn - Houston TX, US
Karel Petrak - Houston TX, US
Jose Engelmayer - Houston TX, US
Assignee:
Agennix, Inc. - Houston TX
International Classification:
A61K 38/00
US Classification:
530324
Abstract:
The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.

Lactoferrin In The Reduction Of Pain

View page
US Patent:
7638487, Dec 29, 2009
Filed:
Nov 29, 2007
Appl. No.:
11/947345
Inventors:
Atul Varadhachary - Houston TX, US
Karel Petrak - Houston TX, US
Assignee:
Agennix, Inc. - Houston TX
International Classification:
A61K 38/00
A61K 38/40
US Classification:
514 6, 514 8, 530350, 530395, 530400, 424 91, 424 851
Abstract:
The present invention relates to methods of using lactoferrin (LF) to reduce pain in conditions associated with severe or intractable pain by administering a composition of lactoferrin either alone or in combination with other therapy for pain.

Lactoferrin In The Treatment Of Malignant Neoplasms And Other Hyperproliferative Diseases

View page
US Patent:
7901879, Mar 8, 2011
Filed:
May 9, 2003
Appl. No.:
10/434769
Inventors:
Atul Varadhachary - Houston TX, US
Rick Barsky - Houston TX, US
Federica Pericle - Houston TX, US
Karel Petrak - Houston TX, US
Yenyun Wang - Houston TX, US
Assignee:
Agennix Incorporated - Houston TX
International Classification:
A61K 38/16
A61P 35/04
US Classification:
435 6, 514 6, 514 12
Abstract:
The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.

Lactoferrin In The Treatment Of Malignant Neoplasms And Other Hyperproliferative Diseases

View page
US Patent:
8242079, Aug 14, 2012
Filed:
Dec 9, 2010
Appl. No.:
12/964327
Inventors:
Atul Varadhachary - Houston TX, US
Rick Barsky - Houston TX, US
Federica Pericle - Houston TX, US
Karel Petrak - Houston TX, US
Yenyun Wang - Houston TX, US
Assignee:
Agennix Incorporated - Houston TX
International Classification:
A61K 38/40
US Classification:
514 192, 514 193
Abstract:
The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.

Formulations For Electroporation

View page
US Patent:
20020025578, Feb 28, 2002
Filed:
Jul 10, 2001
Appl. No.:
09/903009
Inventors:
Fiona MacLaughlin - Belfast, GB
Shulin Li - The Woodlands TX, US
Yuhua Li - The Woodlands TX, US
Karel Petrak - Spring TX, US
Assignee:
Valentis, Inc. - The Woodlands TX
International Classification:
C12N015/87
US Classification:
435/463000
Abstract:
A novel method is provided for delivering nucleic acid molecules to the cells of an organism by pulse voltage delivery. The method involves the combination of formulated nucleic acid molecules with devices for injecting the molecules by pulse voltage or an electrical field. Disclosed are compositions and methods for enhancing the administration to and uptake of nucleic acids in a mammal. The methods disclosed provide an increased transfection and/or gene delivery efficiency by enhancing the uptake of formulated nucleic acid molecules by applying an electrical field which destabilizes the cellular membrane thereby opening pores or passageways which allow extracellular material to be introduced to the cell. Also disclosed are examples which demonstrate that the combination of formulated nucleic acid molecules and pulse voltage injection methods results in immune responses which are superior to those obtained by conventional means of delivery. Methods for delivery, as well as methods for formulating nucleic acid molecules with various compounds, such as cationic complexing agents, polymeric and non-polymeric formulations, protective, interactive, non-condensing systems are also disclosed.

Formulations For Electroporation

View page
US Patent:
20020102729, Aug 1, 2002
Filed:
May 28, 1999
Appl. No.:
09/322602
Inventors:
FIONA MACLAUGHLIN - BELFAST, GB
SHULIN LI - THE WOODLANDS TX, US
YUHUA LI - THE WOODLANDS TX, US
KAREL PETRAK - SPRING TX, US
International Classification:
C12N015/63
C12N015/82
C07H021/02
US Classification:
435/455000, 435/468000, 514/044000, 536/023100
Abstract:
A novel method is provided for delivering nucleic acid molecules to the cells of an organism by pulse voltage delivery. The method involves the combination of formulated nucleic acid molecules with devices for injecting the molecules by pulse voltage or an electrical field. Disclosed are compositions and methods for enhancing the administration to and uptake of nucleic acids in a mammal. The methods disclosed provide an increased transfection and/or gene delivery efficiency by enhancing the uptake of formulated nucleic acid molecules by applying an electrical field which destabilizes the cellular membrane thereby opening pores or passageways which allow extracellular material to be introduced to the cell. Also disclosed are examples which demonstrate that the combination of formulated nucleic acid molecules and pulse voltage injection methods results in immune responses which are superior to those obtained by conventional means of delivery. Methods for delivery, as well as methods for formulating nucleic acid molecules with various compounds, such as cationic complexing agents, polymeric and non-polymeric formulations, protective, interactive, non-condensing systems are also disclosed.
Control profile
Karel L Petrak from Houston, TX, age ~82 Get Report